Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 39, 2012, Pages 15918-15923

  Rousseaux, Maxime W C ^a   Marcogliese, Paul C ^a   Qu, Dianbo ^a   Hewitt, Sarah J ^a   Seang, Sarah ^a   Kim, Raymond H ^b   Slack, Ruth S ^a   Schlossmacher, Michael G ^c,d   Lagace, Diane C ^a   Mak, Tak W ^b   Park, David S ^a,e  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e Pusan National University   (South Korea)

Author keywords

Animal model; Neuritic beading; Neuroinflammation; Neuronal death; PARK7

Indexed keywords

ALPHA SYNUCLEIN; LEUCINE RICH REPEAT KINASE 2;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; DISEASE COURSE; DOPAMINERGIC NERVE CELL; EXOME; GENE SEQUENCE; GENETIC MODEL; LOCUS CERULEUS; MICROGLIA; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA PARS COMPACTA;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LOCUS COERULEUS; MICE; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; ONCOGENE PROTEINS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

ANIMALIA; MUS;

EID: 84866850019     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1205102109     Document Type: Article

References (36)

1. Bonifati V, et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:256-259. (Pubitemid 36131051)
2. Hague S, et al. (2003) Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol 54:271-274. (Pubitemid 36909631)
3. Kitada T, Tomlinson JJ, Ao HS, Grimes DA, Schlossmacher MG (2012) Considerations regarding the etiology and future treatment of autosomal recessive versus idiopathic Parkinson disease. Curr Treat Options Neurol 14:230-240.
4. Ramsey CP, Tsika E, Ischiropoulos H, Giasson BI (2010) DJ-1 deficient mice demonstrate similar vulnerability to pathogenic Ala53Thr human alpha-syn toxicity. Hum Mol Genet 19:1425 -1437.
5. Andres-Mateos E, et al. (2007) DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci USA 104:14807-14812. (Pubitemid 350003224)
6. Chandran JS, et al. (2008) Progressive behavioral deficits in DJ-1-deficient mice are associated with normal nigrostriatal function. Neurobiol Dis 29:505-514.
7. Chen L, et al. (2005) Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem 280:21418-21426. (Pubitemid 40805706)
8. Goldberg MS, et al. (2005) Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45:489-496. (Pubitemid 40249861)
9. Kim RH, et al. (2005) Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci USA 102: 5215-5220.
10. Manning-Boǧ AB, et al. (2007) Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter. Neurobiol Dis 27:141-150. (Pubitemid 47088976)
11. Pham TT, et al. (2010) DJ-1-deficient mice show less TH-positive neurons in the ventral tegmental area and exhibit non-motoric behavioural impairments. Genes Brain Behav 9:305-317.
12. Dawson TM, Ko HS, Dawson VL (2010) Genetic animal models of Parkinson's disease. Neuron 66:646-661.
13. Parkinson Study Group PRECEPT Investigators (2007) Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 69:1480-1490.
14. Waldmeier P, Bozyczko-Coyne D, Williams M, Vaught JL (2006) Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 72: 1197-1206. (Pubitemid 44604283)
15. Snow BJ, et al.; Protect Study Group (2010) A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord 25:1670-1674.
16. Marks WJ, Jr., et al. (2010) Gene delivery of AAV2-neurturin for Parkinson's disease: A double-blind, randomised, controlled trial. Lancet Neurol 9:1164-1172.
17. Perl DP (2011) Neuropathologic Involvement of the Dopaminergic Neuronal Systems in Parkinson's Disease (Blackwell, Oxford), Chap 2, pp 8-10.
18. Song DD, Haber SN (2000) Striatal responses to partial dopaminergic lesion: Evidence for compensatory sprouting. J Neurosci 20:5102-5114. (Pubitemid 30421713)
19. Pritzel M, Huston JP, Sarter M (1983) Behavioral and neuronal reorganization after unilateral substantia nigra lesions: Evidence for increased interhemispheric nigrostriatal projections. Neuroscience 9:879-888. (Pubitemid 13039170)
20. Tekumalla PK, et al. (2001) Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease. Biol Psychiatry 50:813-816. (Pubitemid 33086770)
21. Doucet JP, et al. (1996) Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci 8:365-381.
22. Pérez-Otaño I, Mandelzys A, Morgan JI (1998) MPTP-Parkinsonism is accompanied by persistent expression of a delta-FosB-like protein in dopaminergic pathways. Brain Res Mol Brain Res 53:41- 52.
23. Forno LS, Alvord EC, Jr. (1974) Depigmentation in the nerve cells of the substantia nigra and locus ceruleus in Parkinsonism. Adv Neurol 5:195-202.
24. Takeuchi H, et al. (2005) Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J Biol Chem 280:10444-10454. (Pubitemid 40395902)
25. Greenwood CE, Tatton WG, Seniuk NA, Biddle FG (1991) Increased dopamine synthesis in aging substantia nigra neurons. Neurobiol Aging 12:557-565.
26. Mount MP, et al. (2007) Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci 27:3328-3337. (Pubitemid 46474138)
27. Ouchi Y, et al. (2005) Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 57:168-175. (Pubitemid 40179853)
28. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38:1285-1291.
29. Whitton PS (2007) Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 150:963-976.
30. Nagatsu T, Sawada M (2005) Inflammatory process in Parkinson' s disease: Role for cytokines. Curr Pharm Des 11:999-1016. (Pubitemid 40331301)
31. Von Coelln R, et al. (2004) Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci USA 101:10744-10749. (Pubitemid 38955813)
32. Hayashi A, et al. (2004) Positive regulation of phagocytosis by SIRPbeta and its signaling mechanism in macrophages. J Biol Chem 279:29450-29460. (Pubitemid 38915824)
33. Pahwa RLK, Koller WC (2003) Handbook of Parkinson's Disease (CRC, Boca Raton, FL), 3rd Ed, 597 pp.
34. Crocker SJ, et al. (2001) c-Jun mediates axotomy-induced dopamine neuron death in vivo. Proc Natl Acad Sci USA 98:13385-13390. (Pubitemid 33051372)
35. German DC, Liang CL, Manaye KF, Lane K, Sonsalla PK (2000) Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons. Neuroscience 101:1063-1069.
36. Rosen GD, et al. (2003) Informatics center for mouse genomics: The dissection of complex traits of the nervous system. Neuroinformatics 1:327-342. (Pubitemid 37346049)